Jonathan P Bestwick

2 months ago | adc.bmj.com | Nicholas Wald |Stephen H Vale |Jonathan P Bestwick |Joan Morris

DiscussionThree important conclusions can be drawn from our results. First, there is no discrepancy between the predicted risk reductions based on the two data sets, Daly/Wald and Crider/Chen; the two dose-response slopes are virtually identical. Second, neither dose-response relationship shows a threshold in which an increase in blood folate level ceases to reduce NTD risk.

Sep 19, 2024 | medrxiv.org | Nicholas Wald |Stephen H Vale |Jonathan P Bestwick |Joan Morris

The authors have declared no competing interest. This study did not receive any fundingI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.